Clinical trials in Royal Oak, MI

24 recruiting studies have a site in or near Royal Oak, MI, Michigan.

Top conditions here

All conditions

Showing 24 of 24 studies

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Adrian, MI · Alma, MI · Alpena, MI · +1147 more sites

RecruitingPhase 3NCT06498635

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Sponsor: National Cancer Institute (NCI)

Ann Arbor, MI · Battle Creek, MI · Brighton, MI · +278 more sites

RecruitingNot applicableNCT06898515

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

Sponsor: Reprieve Cardiovascular, Inc

Ann Arbor, MI · Grand Rapids, MI · Royal Oak, MI · +32 more sites

RecruitingPhase 1NCT07310420

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

Sponsor: TerSera Therapeutics LLC

Royal Oak, MI · +25 more sites

RecruitingNot applicableNCT06911632

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

Sponsor: Tempus AI

Ann Arbor, MI · Royal Oak, MI · +38 more sites

RecruitingNot applicableNCT06995898

The Vanguard Study: Testing a New Way to Screen for Cancer

Sponsor: National Cancer Institute (NCI)

Brownstown, MI · Chesterfield, MI · +42 more sites

RecruitingPhase 3NCT06982521

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Sponsor: Relay Therapeutics, Inc.

Ann Arbor, MI · Royal Oak, MI · +50 more sites

RecruitingPhase not listedNCT05334069

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Sponsor: Alliance for Clinical Trials in Oncology

Alma, MI · Alpena, MI · Ann Arbor, MI · +744 more sites

RecruitingPhase 2NCT05673148

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

Sponsor: Alliance for Clinical Trials in Oncology

Ann Arbor, MI · Brighton, MI · +185 more sites

RecruitingPhase 3NCT04649242

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Sponsor: Pfizer

Ann Arbor, MI · Grand Rapids, MI · +166 more sites

RecruitingPhase 3NCT04743141

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

Sponsor: Pfizer

Ann Arbor, MI · Grand Rapids, MI · +112 more sites

RecruitingPhase 3NCT06561386

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Sponsor: Bristol-Myers Squibb

Royal Oak, MI · +55 more sites

RecruitingPhase 3NCT05939414

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Sponsor: Novartis Pharmaceuticals

Grand Rapids, MI · Royal Oak, MI · +36 more sites

RecruitingPhase 1NCT07006727

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Sponsor: Novartis Pharmaceuticals

Royal Oak, MI · +3 more sites

RecruitingPhase 3NCT04293562

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Sponsor: Children's Oncology Group

Ann Arbor, MI · Detroit, MI · +183 more sites

RecruitingPhase 3NCT05879926

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Sponsor: NRG Oncology

Alma, MI · Alpena, MI · Ann Arbor, MI · +1223 more sites

RecruitingPhase 1 / Phase 2NCT04726241

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Sponsor: PedAL BCU, LLC

Ann Arbor, MI · Detroit, MI · East Lansing, MI · +161 more sites

RecruitingPhase 2NCT05287126

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Sponsor: Pfizer

Royal Oak, MI · +18 more sites

RecruitingPhase 3NCT04852887

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Sponsor: NRG Oncology

Ann Arbor, MI · Battle Creek, MI · +809 more sites

RecruitingPhase not listedNCT03448926

The PREDICT Registry:

Sponsor: PreludeDx

Royal Oak, MI · Troy, MI · +28 more sites

RecruitingPhase 3NCT02468024

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

Sponsor: University of Texas Southwestern Medical Center

Detroit, MI · Royal Oak, MI · +38 more sites

RecruitingNot applicableNCT03142152

The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

Sponsor: Cardiac Dimensions, Inc.

Ann Arbor, MI · Royal Oak, MI · Saginaw, MI · +72 more sites

RecruitingPhase not listedNCT04052048

Active Surveillance SNEP Assay Registry Trial for Prostate Cancer

Sponsor: Immunis.AI

Royal Oak, MI

RecruitingPhase 3NCT05929768

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Sponsor: SWOG Cancer Research Network

Adrian, MI · Alma, MI · Alpena, MI · +952 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.